Nuveen Asset Management LLC Has $990,000 Stock Position in UroGen Pharma Ltd. (NASDAQ:URGN)

Nuveen Asset Management LLC trimmed its position in UroGen Pharma Ltd. (NASDAQ:URGN - Free Report) by 37.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 92,957 shares of the company's stock after selling 56,430 shares during the period. Nuveen Asset Management LLC owned approximately 0.40% of UroGen Pharma worth $990,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Renaissance Technologies LLC bought a new position in UroGen Pharma during the fourth quarter worth about $1,472,000. Lazard Asset Management LLC acquired a new stake in shares of UroGen Pharma during the fourth quarter worth about $67,000. Janus Henderson Group PLC bought a new position in shares of UroGen Pharma during the 4th quarter valued at about $149,000. Bank of New York Mellon Corp lifted its holdings in shares of UroGen Pharma by 7.3% during the 4th quarter. Bank of New York Mellon Corp now owns 93,997 shares of the company's stock valued at $1,001,000 after purchasing an additional 6,430 shares in the last quarter. Finally, Oppenheimer & Co. Inc. acquired a new position in shares of UroGen Pharma in the 4th quarter valued at approximately $126,000. Institutional investors own 91.29% of the company's stock.

UroGen Pharma Stock Up 43.4%

Shares of NASDAQ URGN traded up $2.23 during midday trading on Friday, reaching $7.37. The company's stock had a trading volume of 20,043,816 shares, compared to its average volume of 819,904. The stock has a 50 day simple moving average of $8.75 and a 200-day simple moving average of $10.20. The company has a current ratio of 9.00, a quick ratio of 8.77 and a debt-to-equity ratio of 4.77. The stock has a market capitalization of $339.81 million, a price-to-earnings ratio of -2.34 and a beta of 0.66. UroGen Pharma Ltd. has a fifty-two week low of $3.42 and a fifty-two week high of $20.70.

UroGen Pharma (NASDAQ:URGN - Get Free Report) last released its earnings results on Monday, May 12th. The company reported ($0.92) earnings per share for the quarter, missing analysts' consensus estimates of ($0.83) by ($0.09). The company had revenue of $20.25 million for the quarter, compared to analyst estimates of $22.71 million. Equities research analysts predict that UroGen Pharma Ltd. will post -3.12 earnings per share for the current year.

Wall Street Analysts Forecast Growth

URGN has been the topic of several research analyst reports. The Goldman Sachs Group dropped their target price on shares of UroGen Pharma from $16.00 to $3.00 and set a "neutral" rating on the stock in a report on Thursday, May 22nd. Guggenheim lowered their price objective on shares of UroGen Pharma from $40.00 to $15.00 and set a "buy" rating for the company in a research report on Friday, May 23rd. D. Boral Capital restated a "buy" rating and set a $25.00 price objective on shares of UroGen Pharma in a report on Thursday, May 8th. Scotiabank began coverage on shares of UroGen Pharma in a research note on Wednesday, April 16th. They issued a "sector outperform" rating and a $23.00 target price for the company. Finally, HC Wainwright cut UroGen Pharma from a "buy" rating to a "neutral" rating in a report on Thursday, May 22nd. Two research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $23.14.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.